About Addimmune
We Imagine a World Without HIV
Addimmune™ was founded in 2023 to pursue promising gene therapy technologies that treat and cure HIV.
Our revolutionary new gene therapy technology has the power to transform the lives of millions of people living with HIV.
The Power to Transform Millions of Lives
Our gene therapy technology is so effective because it allows us to “edit” a cell’s operating system, its DNA. By editing a cell’s DNA, we can insert or delete commands to change or improve the function of our cells.
AGT103-T Success Deserves Sole Focus
This life-changing approach to HIV has been made possible by 15 years of pioneering research & development by American Gene Technologies (AGT™). AGT created Addimmune as a separate company in 2023.
Why a separate company? Because the Phase 1 clinical trial of AGT103-T (its gene therapy for HIV) was so successful that AGT decided the HIV cure program deserves to be the sole focus of one business.
Addimmune Leadership Team
Jeff Galvin
Founder and CEO
Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of...
Jeff Boyle, PhD
Chief Science Officer
Jeff has over 25 years of research, development, and technical expertise with a deep understanding of biotechnology. Dr. Boyle has held multiple executive roles in the biotech and...
Marcus A. Conant, MD
Chief Medical Officer
Marcus is a physician who treated thousands of HIV patients in the early 80s while running the inpatient dermatology service at the University of California San Francisco.
Nick Tressler, MBA
Chief Financial Officer
Nick Tressler, MBA, is the Chief Financial Officer of American Gene Technologies®. Nick has more than 20 years of experience as a strategic financial executive...
Andrew Miller, CPA
VP of Finance
Andrew has more than 20 years of experience in accounting, finance, strategy, raising capital, and corporate governance in both private companies and non-profit organizations.
Karen McCord
Chief of Staff
Karen McCord has many years of experience building and leading teams in pharmaceutical drug and medical device development. She spent 25 years working in HIV prevention...
Drew Palin, MD
Chief Business Officer
Drew is a bold healthcare entrepreneur with rare expertise encompassing clinical medicine, information technology, and medical devices. He is the founding CEO...
Barry Wells, MD
Head of Business Development
Barry H. Wells, M.D., has devoted his career to eliminating disease. After nearly four decades as a urologist and surgeon treating patients suffering ...
Grant Smith
VP of Marketing and Communications
Grant Smith is the Vice President of Marketing and Communications at Addimmune™. He is an accomplished communications and marketing executive with a rich history...
Lola Liao, CPA
Director of HR & Admin
Lola is Director of Finance and Administration at Addimmune, where she oversees accounting and finance activities and reporting, including tax preparation, Maryland Innovation...
Chris Reid
Systems Development and IT
Chris leads the systems development team and IT department at Addimmune, managing the development, implementation and maintenance...
HIV Scientific Advisory Board
Robert R. Redfield, MD
Senior Advisor to the CEO
W. David Hardy, MD, AAHIVS
Clinical Advisory Board
Charles William Flexner, MD
Clinical Advisory Board
Tommy Thompson
Senior Advisor to the CEO
Michael Saag, MD
Member of Clinical Advisory Board
John J. Rossi, PhD
Member of Clinical Advisory Board
Embrace the Future: Stay at the Forefront of Gene Therapy
Our newsletter delivers expert insights and the latest advancements in gene therapy. Stay informed on our Journey towards a world potentially free from HIV.
